October 3, 2018 6:00 pm
The discussion of race and medicine in the United States is challenging and emotionally charged. Substantial disparities in health outcomes, based on race, ethnicity, and socioeconomic status, continue to exist; additional reports of racial bias and profound insensitivity in research continue to emerge in the popular media. A renewed discussion of race as a biological vs social construct has begun and is complicated by emerging data on genetics, race, and ancestry.
October 2, 2018 9:00 am
Last month, NSF’s biology directorate announced that researchers could submit only one proposal a year in which they are listed as a principal investigator (PI) or co-PI. The cap applies only to the directorate’s three core tracks and excludes several other NSF programs from which many biologists receive support… But 70 scientists have signed onto a letter asking the agency to reconsider the new policy, which they also complain was adopted without any community input.
October 1, 2018 12:30 pm
Finland’s national research funder has signed up to Plan S — a push by a group of European organizations to make a radical change to the way that research results are published. The Academy of Finland, which announced its move on 24 September, is the first organization to sign up since Plan S was launched by 11 funders earlier this month. The now 12-strong coalition demands that, from 2020, papers resulting from the research they fund are immediately free to read on publication.
September 26, 2018 9:00 am
Brii is one of many biotech startups riding a wave of money from Asia that so far this year has poured $4.2 billion into private U.S.-based biotech companies. That is over 43 percent of the total amount of venture funding invested in the biotech sector, according to PitchBook, up from just 11 percent in 2016.
September 20, 2018 6:00 am
Doctors and hospitals love to talk about the cancer patients they’ve saved, and reporters love to write about them. But deaths still vastly outnumber the rare successes.
September 7, 2018 2:07 am
The first test of a new gene-editing tool in people has yielded early clues that the strategy—an infusion that turns the liver into an enzyme factory—could help treat a rare, inherited metabolic disorder. Today, the biotech company Sangamo Therapeutics in Richmond, California, reported data suggesting that two patients with Hunter syndrome are now making small amounts of a crucial enzyme that their bodies previously could not produce. But the company is still a long way from providing evidence that the new method can improve Hunter patients’ health.
August 31, 2018 9:00 am
A lucky group of researchers will soon walk away with £30 million (US$39 million) to study the heart and circulatory system — one of the largest single grants for medical research in the world. The British Heart Foundation (BHF) launched the award on 25 August, and it is open to international applicants.
August 20, 2018 9:00 am
The first thing that went through Alison Avenell’s head when she heard Yoshihiro Sato had died was that it might be a trick. It was March 2017, and in the previous years, Avenell, a clinical nutritionist at the University of Aberdeen in the United Kingdom, had spent thousands of hours combing through Sato’s papers, together with three colleagues in New Zealand. They had discovered that Sato, a bone researcher at a hospital in southern Japan, had fabricated data for dozens of clinical trials published in international journals. “With so much going on, so much fabrication, you just wonder if it’s convenient for the person to go and hide,” Avenell says.
August 15, 2018 9:00 am
Shares in Bayer (BAYGn.DE) plunged more than 10 percent to their lowest in almost two years after a California jury ordered the German company’s subsidiary Monsanto to pay $289 million in damages last week.
July 18, 2018 9:09 am
New research questions the quality of drugs given the “breakthrough therapy” designation by the US Food and Drug Administration. In late 2012, the FDA created this designation to speed the process for reviewing not-yet-approved experimental medicines intended to treat serious or life-threatening conditions.